富瑞:重申合景泰富(1813.HK)為中型股首選 目標價13.17港元
富瑞發表研究報告表示,合景泰富(01813.HK)強勁銷售趨勢使其在11月至12月能加速增長,將同比增長40%,並會在2020財年有額外30%增長。預計其營運穩定能重建投資者的信心,重申其為中型股份的首選股份。該行予其“買入”投資評級,目標價13.17港元。
富瑞表示,合景泰富首10個月已完成80%的銷售目標,預計全年銷售能達857億元人民幣,而2020財年能達1100億元人民幣。該行認為,公司的應占租金收入在2021財年能有30%的複合年增長至35億元人民幣。此外,合景泰富在中國的一、二線城市的有質素的併購能維持高於同業的利潤,預計中期的毛利率將高於30%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.